Premium
Private equity firm Carlyle’s mandatory open offer to acquire a stake of up to 26% in SeQuent Scientific Ltd turned out to be a damp squib as the share price of the animal healthcare company soared. Carlyle managed to acquire only 4,467 shares, or a mere 0.002% of the total 64.57 ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
